NASDAQ:RDUS - Radius Health Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Radius Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.79 -0.18 (-0.90 %) (As of 02/18/2020 01:50 PM ET) Add Compare Today's Range$19.75Now: $19.79▼$20.3050-Day Range$17.56MA: $19.37▼$21.0052-Week Range$17.36Now: $19.79▼$29.97Volume11,980 shsAverage Volume507,355 shsMarket Capitalization$913.70 millionP/E RatioN/ADividend YieldN/ABeta0.89 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDUS Previous Symbol CUSIPN/A CIK1428522 Webhttp://www.radiuspharm.com/ Phone617-551-4000Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$99.24 million Price / Sales9.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book14.88Profitability EPS (Most Recent Fiscal Year)($4.88) Net Income$-221,340,000.00 Net Margins-98.22% Return on Equity-929.94% Return on Assets-58.37%Miscellaneous Employees398 Outstanding Shares46,170,000Market Cap$913.70 million Next Earnings Date2/27/2020 (Confirmed) OptionableOptionable Receive RDUS News and Ratings via Email Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RDUS Rates by TradingView Radius Health (NASDAQ:RDUS) Frequently Asked Questions What is Radius Health's stock symbol? Radius Health trades on the NASDAQ under the ticker symbol "RDUS." How were Radius Health's earnings last quarter? Radius Health Inc (NASDAQ:RDUS) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.15. The biopharmaceutical company had revenue of $46.77 million for the quarter, compared to analysts' expectations of $45.69 million. Radius Health had a negative net margin of 98.22% and a negative return on equity of 929.94%. The business's quarterly revenue was up 69.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.09) earnings per share. View Radius Health's Earnings History. When is Radius Health's next earnings date? Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Radius Health. How can I listen to Radius Health's earnings call? Radius Health will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What guidance has Radius Health issued on next quarter's earnings? Radius Health issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172 million, compared to the consensus revenue estimate of $170.19 million. What price target have analysts set for RDUS? 7 equities research analysts have issued 1 year target prices for Radius Health's stock. Their forecasts range from $27.00 to $43.00. On average, they expect Radius Health's share price to reach $35.00 in the next year. This suggests a possible upside of 76.9% from the stock's current price. View Analyst Price Targets for Radius Health. What is the consensus analysts' recommendation for Radius Health? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health. What are Wall Street analysts saying about Radius Health stock? Here are some recent quotes from research analysts about Radius Health stock: 1. HC Wainwright analysts commented, "Our $26 price target is based on an 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and $300M peak oral Korsuva sales in Stage 3-5 CKD (the latter even further risk-adjusted to <$100M in our model at 30% probability of success pre-Phase 2). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028. If our DCF valuation with IV Korsuva entirely de-risked (and oral still at 30%), all else equal, would yield a CKD-aP driven valuation of $35/share. That does not yet include any explicit value for Korsuva ex-U.S."" (5/9/2019) 2. According to Zacks Investment Research, "Radius’ lead drug, Tymlos, continues to gain traction. In the first six weeks of 2019, the drug captured a 29% share of the U.S. anabolic osteoporosis market and more than 40% of new anabolic patient starts. Tymlos captured, on average, 20% of the U.S. anabolic osteoporosis market in 2018. In the fourth quarter, the drug’s average U.S. anabolic market share grew to 26% and achieved a 39% share of new anabolic patient starts. However, Radius suffered a setback when the European Commission refused to approve the drug. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded with the presence of drugs like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the past twelve months." (5/6/2019) Has Radius Health been receiving favorable news coverage? Press coverage about RDUS stock has trended neutral on Tuesday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Radius Health earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. View News Stories for Radius Health. Are investors shorting Radius Health? Radius Health saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,900,000 shares, an increase of 6.6% from the January 15th total of 6,470,000 shares. Based on an average trading volume of 555,100 shares, the short-interest ratio is presently 12.4 days. Approximately 15.0% of the company's stock are sold short. View Radius Health's Current Options Chain. Who are some of Radius Health's key competitors? Some companies that are related to Radius Health include Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Myokardia (MYOK), Allakos (ALLK), Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS), Intercept Pharmaceuticals (ICPT), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO) and Deciphera Pharmaceuticals (DCPH). What other stocks do shareholders of Radius Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Wells Fargo & Co (WFC), Tandem Diabetes Care (TNDM), Tesla (TSLA) and Ford Motor (F). Who are Radius Health's key executives? Radius Health's management team includes the folowing people: Mr. Jesper Høiland, Pres, CEO & Director (Age 59)Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Brian Nicholas Harvey, Advisor (Age 58)Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board Who are Radius Health's major shareholders? Radius Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (5.12%), Artisan Partners Limited Partnership (2.59%), Emerald Advisers LLC (1.95%), Goldman Sachs Group Inc. (1.84%), FMR LLC (1.52%) and Renaissance Technologies LLC (0.96%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View Institutional Ownership Trends for Radius Health. Which institutional investors are selling Radius Health stock? RDUS stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., FMR LLC, Chicago Equity Partners LLC, UBS Group AG, Citigroup Inc., Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC and Oxford Asset Management LLP. Company insiders that have sold Radius Health company stock in the last year include Anthony Rosenberg, Debasish Roychowdhury and Willard H Dere. View Insider Buying and Selling for Radius Health. Which institutional investors are buying Radius Health stock? RDUS stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Artisan Partners Limited Partnership, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Trust Advisors LP, State of New Jersey Common Pension Fund D and Amia Capital LLP. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health. How do I buy shares of Radius Health? Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Radius Health's stock price today? One share of RDUS stock can currently be purchased for approximately $19.79. How big of a company is Radius Health? Radius Health has a market capitalization of $913.70 million and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis. Radius Health employs 398 workers across the globe.View Additional Information About Radius Health. What is Radius Health's official website? The official website for Radius Health is http://www.radiuspharm.com/. How can I contact Radius Health? Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected] MarketBeat Community Rating for Radius Health (NASDAQ RDUS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 488 (Vote Outperform)Underperform Votes: 374 (Vote Underperform)Total Votes: 862MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective?
